טימנטין 3.2 ג'
glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.
טימנטין 3.2 ג'
glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin as disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.
טיאנם 500 מ"ג
merck sharp & dohme israel ltd - cilastatin sodium 500 mg/vial; imipenem as monohydrate 500 mg/vial - powder for solution for injection - imipenem and enzyme inhibitor - infections caused by susceptible microorganisms.
מנסווקס acwy מנה בודדת
glaxo smith kline (israel) ltd - meningococcal vaccines group a 50 mcg/vial; meningococcal vaccines group c 50 mcg/vial - powder for solution for injection - meningococcus, tetravalent purified polysaccharides antigen - for active immunization of adults and children over two eyars against meningococcal meningitis caused by meningococci of serogroups a, c,w 135 and y meningococci.
בטאפרון
bayer israel ltd - interferon beta 1b - אבקה וממס להכנת תמיסה להזרקה - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
סינכרופרט 6000 יבל וטרינרי
mip veterinaria ltd - serum gonadotrophin - אבקה להכנת תמיסה לזריקה - serum gonadotrophin 6000 iu/vial
סינכרופרט פ.מ.ס.ג'. 600 יבל וטרינרי
mip veterinaria ltd - serum gonadotrophin - אבקה להכנת תמיסה לזריקה - serum gonadotrophin 600 iu/vial
ספייק-וקס
medison pharma ltd - cx-024414 mrna - cx-024414 mrna 1.26 mg/vial - covid-19 vaccines
סרזים 200 יחידות
sanofi - aventis israel ltd - imiglucerase 200 u/vial - powder for solution for infusion - imiglucerase - for the long term enzyme replacement therapy for patients with a confirmed diagnosis of type 1 gaucher disease that results in one or more of the following conditions: - anemia , - thrombocytopenia , - bone disease , - hepatomegaly or splenomegaly.
רקומבינאט iu 250
teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.